UCLA urologist Robert Reiter, MD, discusses GaPSMA PET CT, a new method for detection and visualization of metastatic prostate cancer not previously visible with conventional and molecular imaging techniques. *GaPSMA PET CT is now offered at UCLA and aims to improve management of recurrent and highrisk cancers. Watch more webinars at https://www.uclahealth.org/uclamdchat.

PSMA is now FDA approved for use at UCLA and UCSF.